Intermediate risk tumors do not have MYCN alterations, but demonstrate typical for neuroblastoma chromosomal aberrations: deletion of 11q and gain of 17q, which help to classify the tumors as type 2A. This evidence concerns the gene MYCN and neuroblastoma.